What Are the 7 Stages of Vascular Dementia?

The seven stages of vascular dementia come from the Global Deterioration Scale (GDS), a clinical framework that maps cognitive decline from completely normal functioning all the way to the most severe loss of abilities. Originally developed for Alzheimer’s disease, the GDS has been validated for vascular dementia as well, accurately classifying about 87% of vascular dementia patients in research testing its reliability.¹ The scale gives families and clinicians a shared language for tracking where someone falls on the spectrum, though vascular dementia has its own distinctive progression pattern that does not always follow the smooth downhill slope the numbered stages might suggest.

The Seven Stages at a Glance

Each GDS stage describes a cluster of functional and cognitive abilities. Here is what they look like in practice for someone with vascular dementia:

Stage 1 — No decline: The person has no memory complaints and no detectable problems on clinical testing. Brain changes from vascular disease may already be developing silently, but nothing is noticeable to the person or anyone around them.
Stage 2 — Very mild decline: The person occasionally forgets names or where they left things, but the lapses are subtle enough that friends and family might attribute them to normal aging. Standard cognitive tests still come back normal.
Stage 3 — Mild decline: Problems become noticeable to close family members or coworkers. The person may have trouble finding the right word in conversation, lose track of what they just read, or struggle to organize tasks that used to be routine. This stage roughly corresponds to what clinicians call mild cognitive impairment.
Stage 4 — Moderate decline: Clear deficits show up on clinical assessment. Managing finances, planning meals, or navigating unfamiliar routes becomes genuinely difficult. The person may withdraw from social situations they used to handle comfortably. This is typically where a formal dementia diagnosis is made.
Stage 5 — Moderately severe decline: The person now needs help choosing weather-appropriate clothing and may forget their home address or phone number, though they usually still remember their own name and the names of close family members. They can manage basic personal hygiene with prompting but struggle with more complex tasks.
Stage 6 — Severe decline: Assistance is needed with most daily activities, including dressing, bathing, and toileting. The person may lose awareness of recent events and much of their personal history. Personality changes, agitation, and sleep disruptions become common. They may not consistently recognize family members, though they can usually distinguish familiar faces from strangers.
Stage 7 — Very severe decline: Speech dwindles to a handful of words or is lost entirely. The person loses the ability to walk without assistance, sit up independently, or smile. Swallowing difficulties develop, and full-time care is needed for all activities.

Research comparing vascular dementia patients at GDS stages 2–3 with those at stages 4–6 found significantly greater deficits in memory, overall cognitive ability, and the capacity to handle daily tasks like shopping, managing medications, and handling money in the higher-stage group.¹ That might sound obvious, but it confirms the scale tracks real, measurable differences rather than arbitrary labels.

Why Vascular Dementia Does Not Always Follow a Straight Line

One of the most distinctive things about vascular dementia is how it progresses. Where Alzheimer’s typically shows a gradual, fairly steady decline, vascular dementia often follows a stepwise or fluctuating pattern. A person might remain stable for months or even years, then suddenly drop to a noticeably lower level of functioning after a new stroke or vascular event. Clinical presentations can include acute onset, stepwise decline, a fluctuating course when caused by multiple strokes, or a slow gradual progression when the underlying problem is cerebral small vessel disease.²

A long-term study tracking cognitive change after stroke illustrated this pattern clearly. People who developed dementia within the first three years after a stroke showed a steep, fairly linear decline. But those with longer follow-up periods often had a period of cognitive stability immediately after their stroke that could last anywhere from three to eight years, with steep declines starting only in the roughly three years before a dementia diagnosis was made.³ Some individuals in that study maintained stable cognitive test scores for six or more years before a sudden downturn.⁴

This means the seven-stage framework, while useful, can be misleading if you picture a person smoothly sliding from one stage to the next. In reality, someone with vascular dementia might sit at Stage 3 for years and then jump to Stage 5 after a new vascular event, skipping the gradual transition through Stage 4 that the numbered list implies. The stages describe where someone is, not how quickly or predictably they got there.

What Happens in the Brain

Vascular dementia results from reduced or blocked blood flow to the brain, which damages or kills nerve cells. There are two main forms. Cortical or multi-infarct dementia involves larger strokes, often in the brain’s outer layers. Subcortical vascular dementia, which accounts for more than half of vascular dementia cases, results from damage to deep brain structures caused by tiny strokes in the basal ganglia, thalamus, brainstem, and white matter.⁵

The subcortical form tends to show up first as slowed thinking, trouble with attention and planning, and decreased motor performance rather than the memory loss that most people associate with dementia. This is an important distinction. If you or a family member notice that thinking seems slower, multitasking has become harder, or walking and balance have deteriorated alongside cognitive changes, those are hallmarks of vascular damage in deep brain regions rather than the cortical atrophy pattern typical of Alzheimer’s. In fact, motor performance has been found to be a strong predictor of declining ability to perform basic daily tasks in vascular dementia patients, even more so than deficits in attention and executive function alone.⁶

Catching It Early Makes a Real Difference

One of the frustrating realities of vascular dementia is that the earliest stages are often missed entirely. Community-dwelling older adults with vascular mild cognitive impairment frequently go undetected and are not clinically identified until they develop obvious dementia.⁷ This matters enormously because the vascular risk factors behind the disease, such as high blood pressure, diabetes, and high cholesterol, are treatable. Appropriate treatment of those risk factors can prevent or delay progression to full dementia.

At the mild cognitive impairment stage (roughly Stage 3 on the GDS), a person is still independent but performs tasks with more effort than before. They may resort to compensatory strategies, struggle with multitasking, complain of mental fatigue, make more errors in their work, have noticeable word-finding difficulties, or need extra help navigating.⁸ These changes are easy to dismiss as stress or aging, which is exactly why so many cases slip through. There is a compounding problem: people with undetected vascular mild cognitive impairment often have decreased ability to follow their medication regimens, and that poor adherence worsens the very cardiovascular conditions driving the cognitive decline.⁷

The broader concept of vascular cognitive impairment, which covers the full range of cognitive deficits from mild impairment to dementia, exists precisely to encourage identification at the earliest possible stage, when treatment has the greatest opportunity to slow progression.⁹

Blood Pressure and Dementia Risk

Among modifiable risk factors, high blood pressure has the strongest evidence linking it to vascular dementia. Treating hypertension does not just protect the heart; it appears to meaningfully protect the brain. In one landmark trial, active blood pressure treatment cut dementia incidence in half over two years compared with placebo, and prolonged follow-up strengthened the finding, showing that sustained antihypertensive treatment reduced dementia risk by about 55%.¹⁰ A large more recent trial found that aiming for a lower blood pressure target (below 120 mmHg systolic rather than the standard 140) produced a significantly lower incidence of both mild cognitive decline and dementia.¹⁰

Treating hypertension in midlife, rather than waiting until cognitive symptoms appear, may be especially important. If antihypertensives are confirmed beneficial by larger-scale trials with longer follow-up, treatment of high blood pressure in middle age could be one of the most effective strategies for lowering dementia rates at a population level.¹¹

How Vascular Dementia Is Diagnosed

There is no single test for vascular dementia. Diagnosis involves cognitive testing, brain imaging, and a clinical picture consistent with vascular disease. Two widely used screening tools are the Montreal Cognitive Assessment (MoCA) and the Mini-Mental State Examination (MMSE). Both show excellent accuracy in distinguishing vascular dementia from healthy controls, with the MoCA achieving particularly strong performance in separating even the milder vascular cognitive impairment stage from normal cognition.

Brain MRI plays a central role. A meta-analysis found that all patients in a vascular dementia group had high white matter signal abnormalities on MRI, and they had larger volumes of these abnormalities compared with cognitively normal people, those with mild impairment, and even those with Alzheimer’s disease. Irregular patterns of white matter changes, particularly those surrounding the brain’s fluid-filled ventricles, were especially characteristic of vascular dementia.¹² Interestingly, deeper white matter changes (as opposed to the changes right around the ventricles) may be more useful for telling vascular dementia apart from Alzheimer’s, achieving about 86% classification accuracy in one study.¹³

Researchers are also working on blood-based biomarkers that could one day make screening easier and more accessible. The search for markers tied to neuronal function is a growing area of investigation, though no single blood test can yet diagnose vascular dementia on its own.¹⁴

Treatment Options

This is where the picture gets honest and a little disappointing. No drug has been approved by the U.S. Food and Drug Administration specifically for vascular dementia. However, donepezil, rivastigmine, and memantine, all originally developed for Alzheimer’s, have some evidence as cognitive enhancers in vascular dementia patients and are approved for that use in several countries outside the United States, including New Zealand, India, South Korea, and various Latin American nations.¹⁵

A large network meta-analysis comparing 21 different drugs used for vascular dementia across nearly 200 randomized trials found that several compounds improved cognitive test scores and daily functioning. The drugs that performed best for cognitive scores included butylphthalide, huperzine A, edaravone, rivastigmine, and memantine, while the top performers for daily living ability included huperzine A, butylphthalide, and nicergoline.¹⁶ Many of the better-performing drugs in that analysis are used primarily in Chinese clinical practice, which reflects genuine differences in how vascular dementia is treated around the world. Herbal extracts including butylphthalide and Ginkgo biloba are advocated in Chinese jurisdictions.¹⁵

Beyond existing drugs, novel treatment strategies such as noninvasive brain stimulation, stimulant medications, and neurotrophic factors are being explored.¹⁵ For now, though, the most effective intervention remains managing the underlying vascular risk factors to prevent further brain damage. Controlling blood pressure, managing diabetes, treating high cholesterol, stopping smoking, and staying physically active are the backbone of vascular dementia care.

When Vascular Dementia Overlaps with Alzheimer’s

In clinical practice, a clean diagnosis of “pure” vascular dementia is less common than many people assume. Mixed dementia, most often a combination of Alzheimer’s disease and vascular pathology, is extremely common, especially in older adults.¹⁷ The two diseases are not just side-by-side roommates in the brain; vascular factors can accelerate or worsen Alzheimer’s pathology, creating a feedback loop where each condition makes the other worse.

This overlap complicates the staging question. A person with mixed dementia may show some features typical of vascular decline (stepwise drops, early executive dysfunction, motor problems) alongside features more common in Alzheimer’s (gradual memory loss, language decline). Their progression through the GDS stages may not fit neatly into either disease’s expected pattern. If you are caring for someone whose symptoms seem to fit both descriptions, mixed pathology is a real possibility worth discussing with their clinician.

Survival and Prognosis

Vascular dementia tends to have a shorter survival time than Alzheimer’s disease. A large study using data from the National Alzheimer’s Coordinating Center found that individuals with Alzheimer’s had a median survival of six years from diagnosis, compared with four years for vascular dementia.¹⁸ That shorter survival likely reflects the fact that people with vascular dementia carry a heavy burden of cardiovascular disease, which independently raises the risk of heart attack, stroke, and death from vascular causes, not just from the dementia itself. The prognosis of vascular mild cognitive impairment includes not only the risk of progressing to dementia but also death from cardiovascular disease.⁷

Individual trajectories vary widely, of course. Some people remain in the earlier stages for years, especially if vascular risk factors are well controlled. Others decline rapidly after a major stroke. The stepwise nature of the disease means prognosis depends heavily on whether additional vascular events can be prevented.

Inherited Forms of Vascular Dementia

Most vascular dementia is driven by the usual cardiovascular risk factors, but a small subset has a genetic basis. The most common inherited form is CADASIL, a cerebral small vessel disease caused by mutations in the NOTCH3 gene. People with CADASIL develop recurrent small strokes and progressive vascular dementia, often starting in midlife rather than old age.¹⁹ Even within families carrying the same mutation, the nature and timing of symptoms vary considerably, meaning a diagnosis of CADASIL in one family member does not predict an identical course in another. If vascular dementia or recurrent strokes appear at an unusually young age, or if multiple family members have been affected, genetic testing for conditions like CADASIL may be worth pursuing.

1
PubMed. The global deterioration scale: relationships to neuropsychological performance and activities of daily living in patients with vascular dementia
2
PubMed Central. Vascular Cognitive Impairment and Dementia: Clinical Features, Neuropathology, and Biomarkers
3
PubMed Central. Trajectories of cognitive change following stroke: stepwise decline towards dementia in the elderly
4
Brain Communications. Trajectories of cognitive change following stroke: stepwise decline towards dementia in the elderly
5
PubMed Central. Small vessel disease and subcortical vascular dementia
6
PubMed. Cognitive and motor impairments predict functional declines in patients with vascular dementia
7
PubMed Central. Vascular Mild Cognitive Impairment: Identifying Disease in Community-Dwelling Older Adults, Reducing Risk Factors, and Providing Support
8
PubMed Central. Diagnostic criteria for vascular cognitive disorders: a VASCOG statement
9
PubMed. Vascular Cognitive Impairment
10
PubMed Central. Hypertension and the Risk of Dementia
11
Pharmacology & Therapeutics. Hypertension & dementia: Pathophysiology & potential utility of antihypertensives in reducing disease burden
12
PubMed Central. White matter hyperintensities and the risk of vascular dementia: a systematic review and meta-analysis
13
PubMed Central. Peripheral (deep) but not periventricular MRI white matter hyperintensities are increased in clinical vascular dementia compared to Alzheimer’s disease
14
PubMed Central. Blood biomarkers for vascular cognitive impairment based on neuronal function: a systematic review and meta-analysis
15
Neuropsychopharmacology. Vascular cognitive impairment and dementia: Prevention, treatments, mechanisms and management options for the future
16
Frontiers in Pharmacology. Pharmacological treatments for vascular dementia: a systematic review and Bayesian network meta-analysis
17
PubMed Central. The pathophysiology of mixed Alzheimer’s disease and vascular dementia
18
PubMed Central. Predictors of Mortality in Individuals with Dementia in the National Alzheimer’s Coordinating Center
19
PubMed. Management of Inherited CNS Small Vessel Diseases: The CADASIL Example: A Scientific Statement From the American Heart Association